Introduction: Many lifestyle habits can negatively affect sleep quality (SQ) and lead to poor quality of life. This makes it important to determine the prevalence of poor SQ in the population and the lifestyle habits that may be associated with it, with a view to designing appropriate interventions for improving SQ. The aim of this study was to examine the prevalence of poor SQ among the population of Salamanca (Spain) and its relationship with specific lifestyle habits Method: A cross-sectional study was carried out between July and November 2019. SQ was studied in 261 patients using the Pittsburgh Sleep Quality Index, and the frequency with which patients performed a series of lifestyle habits was quantified. The association between variables was assessed using multivariate binary logistic regression. Results: Almost half of the study population (48.7%) was found to have poor SQ. Physical exercise was a protective factor against poor SQ (OR = 0.221; CI95%: 0.081-0.603). Risk factors for poor SQ included being disturbed at night (OR = 3.606; CI95%: 1.892-6.872), going to bed preoccupied (OR = 3.145; CI95%: 1.528-6.471), reading trivial material (OR = 2.475; CI95%: 1.208-5.070), and playing video games (OR = 3.639; CI95%: 1.326-9.984). Conclusions: In Salamanca (Spain), almost half of the study population stated that they suffered poor SQ. Although numerous lifestyle habits that may relate to poor SQ were studied, a statistically significant relationship was only found for a few of them.

Este trabajo fue enviado al X Congreso Nacional de Farmacéuticos Comunitarios, resultando premiado con el Premio revisa a la mejor comunicación de SPFA en revisión del uso de los medicamentos.

Introducción: En los últimos años ha habido un incremento de la participación de farmacias comunitarias en proyectos de investigación. El reclutamiento de pacientes juega un papel clave en el éxito de las investigaciones. Se han identificado barreras y facilitadores que promueven dicho reclutamiento por parte de los farmacéuticos, pero poco es sabido sobre la influencia de factores relacionados con los proyectos de investigación. El objetivo de este trabajo es observar la participación en diferentes investigaciones llevadas a cabo en farmacias comunitarias e identificar las variables propias de los estudios que puedan estar asociadas con la participación. Método: Se realizó un estudio multicéntrico experimental en 12 farmacias comunitarias que formaron parte de 4 proyectos de investigación. Se registró el número de pacientes que aceptaron/rechazaron participar. Se recogieron variables relacionadas con el estudio ofrecido y las farmacias. Se realizó un análisis bivariante mediante la prueba Chi-Cuadrado de Pearson y un análisis de los riesgos. Resultados: La participación total fue del 90,44% (n=558). El tipo de estudio (OR=2,64; 95%IC=1,47-4,75; transversal vs pragmático), el tipo de medida aplicada (OR=2,47; 95%IC=1,43-4,36), la aplicación de zona de atención personalizada (ZAP) (OR=2,49; 95%IC=1,44-4,39), y la solicitud de datos personales (OR=2,53; 95%IC=1,47-4,42) mostraron asociación con la participación en los PI (p<0,05). Conclusiones: La participación por parte de los pacientes en proyectos de investigación es elevado y parece depender de factores propios del estudio aplicado.

Introduction: Chondroitin sulfate was proposed as a more appropriate strategy for osteoarthritis long-term management than conventional treatment (nonsteroidal anti-inflammatory drugs and acetaminophen). However, its efficacy has been widely discussed and its public financing by the Spanish National Health System has been questioned. The aim of this paper was review on the clinical and economic aspects of chondroitin sulfate in osteoarthritis treatment. Method: A bibliographic search of recent literature was carried out until March 9th, 2022. The databases used were MEDLINE and Scopus. Results: According to the set of clinical studies identified in the search, chondroitin sulfate was effective in reducing cartilage volume loss, its clinical effects were estimated by objective (magnetic resonance or specific biomarkers) and subjective (visual analog pain scale or Lequesne index) outcome measures. In the set of studies reviewed, chondroitin sulfate proved to be an acceptable therapeutic option in clinical terms. Regarding economic aspects, only one study was identified, according to which, the prescription of chondroitin sulfate implies a lower cost per patient compared to non-steroidal anti-inflammatory drugs. Conclusion: From the clinical and economic points of view, the findings of this brief review justify the presence of chondroitin sulfate in osteoarthritis guidelines.